Networks of Centres of Excellence NCE Program - PowerPoint PPT Presentation

Networks of Centres of Excellence NCE Program (http://www.nce-rce.gc.ca/) • ‰ Federal research funding program • ‰ Partnership between Canada’s three funding agencies, Health Canada and Industry Canada Mission “To mobilize Canada’s research talent in the academic, private and public sectors and apply it to the task of developing the economy and improving the quality of life of Canadians”

Current Classic NCEs (14) A classic NCE has roughly $15-36 Million (CAD) over 5 years (renewable twice) Environmental science and technologies (3) : Health and related life sciences and technologies (8): • ‰ ArcticNet • ‰ AllerGen • ‰ Canadian Water Network (CWN) • ‰ Stem Cell Network • ‰ Marine Environmental, Observation, Prediction and Response Network • ‰ NeuroDevNet (EOPAR) • ‰ TVN (tech for the elderly) Natural resources and energy (1): • ‰ AGE-WELL (aging) • ‰ BioFuelNet • ‰ BioCanRx (cancer) • ‰ CANet (arrhythmia) Information and communication • ‰ GlycoNet (carbohydrate chem) technologies (1): • ‰ Graphics, Animation and New Media Canada (GRAND) Manufacturing (1) • ‰ AUTO21 Social Sciences and Wellness (0)

NCE Program Criteria Successful networks demonstrating excellence in each of the following criteria: Management of the Network 1. ‰ Excellence of the Research Program 2. ‰ Development of Highly Qualified Personnel 3. ‰ Networking and Partnerships 4. ‰ Knowledge and Technology Exchange and Exploitation 5. ‰

Additional Review Criteria Networks must: • ‰ Be solution-driven and involve partners and the receptor community • ‰ Demonstrate world-class capacity and develop international collaborations to contribute to Canada’s international leadership • ‰ Advance knowledge and/or technology for the benefit of Canadian society • ‰ Outline the impacts the Network will provide within the funding cycle • ‰ Outline a plan for lasting value and long term impacts • ‰ Build on established collaboration

2015 NCE Network Competition 83 Letters of Intent (LOIs) 10 applications selected to proceed to Full Application 4 networks funded: • ‰ AGE-WELL - Aging Gracefully Across Environments Using Technology to Support Wellness, Engagement and Long Life • ‰ BioCanRx - Biotherapeutics for Cancer Treatment • ‰ CANet - Canadian Arrhythmia Network • ‰ GlycoNet - Canadian Glycomics Network

7 CANet - VISION Vision Transform Canada’s arrhythmia healthcare system: • ‰ to be effective, accessible, and sustainable; • ‰ with innovative technologies to empower patients to manage their care; • ‰ and producing economic growth and prosperity Mission • ‰ Multidisciplinary, multi-sectoral research programs • ‰ Generate novel technologies and health strategies

8 What CANet-ReCAr will do? • ‰ The Network will create: • ‰ Tools for the right hands at the right time • ‰ Tools to empower Canadian to manage their own health • ‰ Tools to empower caregivers to improve patient care at the bedside and in the community • ‰ Tools to empower the healthcare system to provide timely, effective, and efficient services to people and populations

9 Value Propositions A) Clinical (10-year) 10% drop in sudden cardiac death • ‰ 20% drop in atrial fibrillation hospitalization and ED visits • ‰ 30% drop in syncope hospitalization and ED visits • ‰ B) Commercialization (5-year) • ‰ 5-7 new technologies C) Highly Qualified Personnel (5-year) • ‰ 30-40 new talents launched in public and private research

10 CANet Research Excellence • ‰ Our ¡research ¡programs ¡are ¡aligned ¡with ¡the ¡3 ¡themes: ¡ ¡ Theme ¡1 ¡ Invent ¡ ¡Technological ¡ innova&ons ¡ ¡ Theme ¡2 ¡ Prove ¡ ¡Safe, ¡effec=ve, ¡cost ¡effec=ve ¡ solu&ons ¡ Theme ¡3 ¡ Implement ¡ ¡ Transforming ¡healthcare ¡through ¡empowering ¡ pa=ents ¡and ¡caregivers ¡and ¡implemen=ng ¡ solu=ons ¡ • ‰ To ¡deliver ¡the ¡clinical ¡outcomes ¡in ¡5-­‑10 ¡years, ¡research ¡ programs ¡must ¡not ¡only ¡be ¡focused, ¡but ¡also ¡bold, ¡cohesive ¡ and ¡complementary ¡

11 Research Excellence Impact Achieved

12 Network Core Value A cultural change Paternalism Patient Centered care Partnership of care INFORMING CONSULTING INVOLVEMENT CO-BUILDING CO-LEADERSHIP

Additional aspects of the Network In addition to the Network’s research activities, we will also focus on: Development of Highly Qualified Personnel (Training program) 1. ‰ Define: Develop and retain the next generation of researchers. Networking and Partnerships 2. ‰ Define: Engage partners from multiple sectors (academia, industry, government, not-for- profit organizations, etc.) to define needs, develop research questions, guide the research process, and validate and implement solutions. Knowledge and Technology Exchange and Exploitation 3. ‰ Define: Translation of knowledge and technology created by our Network’s research to users (patients, clinicians, health services managers, and policy makers) to optimize high quality care and/or to commercial enterprises to generate economic benefits for Canada.

14 Management Execu=ve ¡ CommiGee ¡(EC) ¡ Ethics ¡& ¡Conflict ¡of ¡ Interest ¡CommiGee ¡ (ECOIC) ¡ CANet-­‑ReCAr ¡ Audit ¡& ¡Finance ¡ CommiGee ¡(AFC) ¡ Board ¡of ¡Directors ¡ Business ¡ Development ¡ Performance ¡ CommiGee ¡(BDC) ¡ Management ¡ CommiGee ¡(PMC) ¡ Scien=fic ¡Director/ CEO ¡ Interna=onal ¡Expert ¡ Training ¡& ¡Educa=on ¡ Advisory ¡CommiGee ¡ CommiGee ¡(TEC) ¡ (IEAC) ¡ Research ¡Management ¡ CommiGee ¡(RMC) ¡ Technology ¡& ¡Health ¡ Pa=ent ¡Advisory ¡ Solu=ons ¡CommiGee ¡ CommiGee ¡(PAC) ¡ (THSC) ¡ Administra=ve ¡ CANet-­‑ReCAr ¡network ¡ Centre ¡

15 28 Academic Institutions

16 Industry Partnership

17 Not-for-profit Partnership

Preventing Stroke due to Atrial Fibrillation: The next 10 years … Jeff Healey MD

Canadian AF-Stroke Research

Trial Field Journal Year CTOPP Pacemaker (AF, stroke) NEJM 2000 CTAF AF, Rhythm Control NEJM 2000 AFFIRM AF, Rate vs. Rhythm Control NEJM 2002 OAC meta-analysis AF, OAC JAMA 2002 VPS-II Pacemaker, Vasovagal JAMA 2003 PABABEAR AF, Rhythm Control JAMA 2005 ACTIVE-W AF, Stroke, OAC Lancet 2006 AF-CHF AF, Rhythm Control NEJM 2008 ACTIVE-A AF, Stroke, OAC NEJM 2009 RE-LY AF, Stroke, OAC NEJM 2009 ACTIVE-I AF, Stroke, HTN NEJM 2011 AVERROES AF, Stroke, OAC NEJM 2011 ASSERT AF, Stroke NEJM 2012 CORONARY CABG, Stroke NEJM 2012 SP-3 Stroke NEJM 2012

64% (95%CI 49,74) Hart RG, Pearce LA, Aguilar MI. Ann Intern Med 2007: 146: 857-67.

Individual outcomes in 4 large randomized trials comparing DOACs with high-quality warfarin anticoagulation* Data shown are for higher dosages of dabigatran (150mg twice daily) and edoxaban (60mg daily). Ruff CT et al. Lancet 2013 (on-line Dec 4 th )

Drug-Based Rhythm Control AFFIRM: G. Wyse, NEJM 2002 AF-CHF: D. Roy, NEJM 2008

RAAFT: C. Morillo – JAMA 2014 58% 41% HR: 0.52 (0.30 – 0.89) p= 0.01

AS ymptomatic AF and S troke E valuation in Pacemaker Patients and the AF R eduction Atrial Pacing T rial

Time to First Device-Detected Atrial Tachyarrhythmia > 6 min, >190 bpm ASSERT : Time to Adjudicated AHRE(>6 minutes,>190/minute) # at Risk Year 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.6 2580 2059 1842 1663 1371 1008 706 446 243 Cumulative Hazard Rates 0.5 0.4 0.3 3 month Visit 0.2 0.1 0.0 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 Years of Follow-up

C-­‑SPIN ¡Official ¡Announcement ¡ October ¡1 st , ¡2013 ¡Approval ¡for ¡ Funding ¡ OCTOBER 1 ST , 1013 OFFICIAL APPROVAL FOR FUNDING ¡ ¡ ¡

Stroke Prevention Vision High-Risk/Intensity Patients: CV surgery, Stroke Pacemaker, Risk Cryptogenic stroke Intensity Moderate Risk/ of Intensity Patients: Medical ER, Family practice Care Low Risk/Intensity Patients: General Population

C-­‑SPIN ¡Goals ¡ Develop randomized trials for stroke prevention in AF: answer clinical and mechanistic questions – ‰ Fund pilots, vanguard, bridge funding Develop a sustainable framework for attracting and nurturing the next generation of Canadian AF and Stroke researchers Develop a strategy for cost-effective translation of scientific results into health-care delivery Capitalize on innovations in AF detection and anticoagulation